Ind-Ra expects fiscal deficit to touch 7.6 per cent in FY21
Ind-Ra expects fiscal deficit to touch 7.6 per cent in FY21

Ind-Ra expects fiscal deficit to touch 7.6 per cent in FY21

Amir Shaikh Article rating: 5.0

India Ratings and Research (Ind-Ra) in its latest report stated that the government's fiscal deficit is estimated to touch 7.6 per cent in FY21, more than double the Budget Estimate (BE), as the nation spends extra to lessen the impact of the COVID-19 pandemic while facing a shortfall in incomes

Five stocks with buying interest
Five stocks with buying interest

Five stocks with buying interest

Ganesh Pawar Article rating: 3.7

The market opened in the green on July 20, 2020, overall volumes in futures & options currently stand at 1,72,21,668 crore contracts with a turnover of Rs. 10,75,163.07 crore.

Five stocks with selling interest
Five stocks with selling interest

Five stocks with selling interest

Ganesh Pawar Article rating: 3.5

The market opened in the green on July 20, 2020, overall volumes in futures & options currently stand at 1,72,21,668 crore contracts with a turnover of Rs. 10,75,163.07 crore.

Byke Hospitality faces low occupancy pressure due to COVID-19
Byke Hospitality faces low occupancy pressure due to COVID-19

Byke Hospitality faces low occupancy pressure due to COVID-19

Apurva Joshi Article rating: 3.6

Byke Hospitality has also faced the brunt of the pandemic on its business operations. As it was not part of government denominated essential services, most of the hotels of the company were shut down entirely during the lockdown.

Glenmark Pharma down by 5 per cent on charges of FabiFlu overpricing
Glenmark Pharma down by 5 per cent on charges of FabiFlu overpricing

Glenmark Pharma down by 5 per cent on charges of FabiFlu overpricing

Nidhi Jani Article rating: 4.5

In a letter to the company, Drug controller Dr VG Somani said that a Member of Parliament (MP) has informed that the cost of treatment from FabiFlu (Favipiravir) will come to around Rs 12,500, which is not good for the poor as well as the middle-class families.

Zydus Cadila gets USFDA approval to treat tension headache
Zydus Cadila gets USFDA approval to treat tension headache

Zydus Cadila gets USFDA approval to treat tension headache

Nidhi Jani Article rating: 4.6

The company has received approval to market Butalbital, Acetaminophen and Caffeine medicines in the strengths of 50 mg/325 mg/40 mg. This combination of medicines is used in the treatment of patients suffering from symptoms of tension headaches.

VIP Industries on verge of giving symmetrical triangle breakout
VIP Industries on verge of giving symmetrical triangle breakout

VIP Industries on verge of giving symmetrical triangle breakout

Vinayak Gangule Article rating: 3.4

Since the last 31 trading sessions, the stock is trading in contracting consolidation, which resulted in the formation of a symmetrical triangle pattern. As of now, the momentum in prices has been narrowed substantially and its prices have reached near an apex point of the triangle, which suggests that the stock is likely to give a breakout in the coming days.

Technical stocks to watch out for Intraday
Technical stocks to watch out for Intraday

Technical stocks to watch out for Intraday

Vinayak Gangule Article rating: 3.2

Due to a narrow range, Bollinger Bands have contracted, which indicates an early signal of a bigger move. Also, on the lower timeframe, i.e. 60 minutes, the stock is on the verge of giving a breakout of downward sloping trendline.

RSS
First20712072207320742076207820792080Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR